Journal of pediatric hematology/oncology · 2026
Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Catueno Samanta, Frost Maria, Cuglievan Branko, Gibson Amber, McCall David, Nunez Cesar, Roth Michael, Malpica Luis, Garcia Miriam B
Аннотация
BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma that, rarely, can present with secondary haemophagocytic lymphohistiocytosis (HLH).
OBSERVATIONS: A 6-year-old boy with ALK-positive ALCL and HLH required intensive care and chemotherapy, experienced multiple relapses, and ultimately achieved remission with crizotinib, ruxolitinib, dexamethasone, and allogeneic stem cell transplant.
CONCLUSIONS: This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.
OBSERVATIONS: A 6-year-old boy with ALK-positive ALCL and HLH required intensive care and chemotherapy, experienced multiple relapses, and ultimately achieved remission with crizotinib, ruxolitinib, dexamethasone, and allogeneic stem cell transplant.
CONCLUSIONS: This case illustrates the clinical challenges of treating ALK-positive ALCL with concurrent HLH and highlights the role of targeted therapies. As molecular understanding of ALCL increases, integrating novel targeted agents may improve outcomes, particularly in relapsed or high-risk disease.